NCT05912933View on ClinicalTrials.gov

A Study to Learn About the Relationship Between Hepatic Impairment and Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal-bow-sai-klib)

CompletedOBSERVATIONAL
Enrollment

733

Participants

Timeline

Start Date

August 19, 2024

Primary Completion Date

August 30, 2024

Study Completion Date

August 30, 2024

Conditions
Breast Cancer
Trial Locations (1)

10001

Pfizer New York, New York

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05912933 - A Study to Learn About the Relationship Between Hepatic Impairment and Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal-bow-sai-klib) | Biotech Hunter | Biotech Hunter